Nanobiotix reports positive results and strong financial standing, expects significant clinical milestones

From GlobeNewswire: 2024-09-18 16:15:00

Nanobiotix’s RT-NBTXR3 combined with anti-PD-1 shows promise in patients naïve and resistant to anti-PD-1. Positive results include disease control and tumor response. The company expects significant clinical milestones in the next 12-18 months, with a strong financial standing of €66.3 million in cash as of June 30, 2024, extending cash runway to Q4 2025.

Nanobiotix reported operational progress and financial results for the first half of 2024. The company continues to advance NBTXR3 with global collaborations and clinical trials in various cancers. New data from Study 1100 presented at ASCO showed promising results in head and neck cancer patients, supporting the potential for NBTXR3 in combination with immunotherapy.

Key clinical milestones include updated data in pancreatic and head and neck cancer, and initial data in esophageal and lung cancer expected over the next 12-18 months. Study 102 and Study 1100 demonstrated positive responses in patients with head and neck cancer resistant to anti-PD-1, indicating the potential for NBTXR3 to prime the immune system.

Nanobiotix’s strategic collaboration with MD Anderson Cancer Center aims to expand NBTXR3’s therapeutic profiles. Ongoing trials in advanced solid tumors across different cancers are progressing well, with multiple milestones expected in the coming months. Financially, revenue has increased, and the company’s cash position of €66.3 million provides a stable foundation for future operations.



Read more at GlobeNewswire:: NANOBIOTIX Provides Business Update and Reports Half Year